Incyte Stock Eyes Worst Day Since 2018 After Trial Results

Shares are gapping below technical support

Fernanda Horner

Digital Content Manager

Mar 17, 2025 at 10:44 AM

INCY

Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective for half of participants.

Shares are on pace for their fourth loss over the last five sessions, as well as their biggest single-day percentage drop since 2018. The equity earlier gapped to its lowest level since July, breaking below $65, which contained several pullbacks since November. In the last three months, INCY shed over 13%.

Amid low absolute volume, Incyte stock has seen seven times the overall options volume typically seen at this point. Most active is the April 60 call, where new positions are being sold to open.

Short-term players leaned bullish prior to the results. This is per Incyte stock's Schaeffer's put/call open interest ratio (SOIR), which sits in the low 14th percentile of its annual range.

Follow @Schaeffers

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.